|1.||Egawa, Y: 1 article (06/2000)|
|2.||Miyamoto, K: 1 article (06/2000)|
|3.||Sadzuka, Y: 1 article (06/2000)|
|4.||Sonobe, T: 1 article (06/2000)|
|5.||Sawanishi, H: 1 article (06/2000)|
|6.||Sugiyama, T: 1 article (06/2000)|
04/26/1999 - "Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia."
06/01/2000 - "The effects of 1-methyl-3-propyl-7-butylxanthine (MPBX), a xanthine derivative, on idarubicin (IDA)-induced antitumor activity against P388 leukemia cells (P388) and bone marrow suppression were examined. "
04/26/1999 - "The effects of 1-methyl-3-propyl-7-butylxanthine (MPBX), a xanthine derivative, on doxorubicin (DOX)-induced antitumor activity against DOX-sensitive P388 leukemia (P388) and DOX-resistant P388 leukemia (P388/DOX) have been examined. "
|3.||Drug Toxicity (Drug Safety)
02/01/1998 - "Thus, the combination of XT-77 with adriamycin not only increased the antitumor activity of adriamycin, but also decreased the adverse drug reactions."
02/01/1998 - "Furthermore, XT-77 reduced the adverse drug reactions of adriamycin by decreasing the adriamycin concentrations in the heart and the liver. "
|3.||Idarubicin (4 Demethoxydaunorubicin)